Home / Pharma News

Pharma News

Top 10 most read GaBI Online articles in 2012

2012 was a busy year with lots of developments in biosimilars from regulatory guidelines to comparability issues.  Biosimilars remain as the hot topic of the year for GaBI Online.

Brand-name drugmaker can be sued for harm caused by generic drug

On 4 January 2013 the Alabama Supreme Court ruled that Pfizer can be sued for failing to warn about a drug’s risks by a patient who claimed he was injured by a generic version of its gastric reflux medicine Reglan (metoclopramide).

Teva makes South Korean joint venture agreement

Teva Pharmaceutical Industries (Teva) announced on 16 December 2012 that it had made an agreement with Handok Pharmaceuticals (Handok) to establish a business venture in South Korea.

Teva cost-cutting and re-organization

Teva Pharmaceutical Industries’ (Teva’s) new Chief Executive vowed to reshape the drugmaker and reduce annual costs by up to US$2 billion over the next five years, making it into ‘the most indispensable medicines company in the world’.

Eli Lilly and Strides Arcolab in generics deal

Pharma giant Eli Lilly and India-based generics manufacturer Strides Arcolab announced on 5 December 2012 a collaboration to market the latter’s generic cancer drugs in emerging markets.

Sanofi to acquire Colombian generics maker

Healthcare major Sanofi announced on 2 October 2012 that it has signed an agreement to acquire Colombian generics manufacturer Laboratorios Genfar (Genfar), making Sanofi a market leader in Colombia and expand its portfolio of affordable pharmaceuticals in Latin America.

GPhA drug shortages plan gets FTC approval

On 8 August 2012 the US Federal Trade Commission (FTC) issued a positive advisory opinion to the Generic Pharmaceutical Association (GPhA) approving its Accelerated Recovery Initiative (ARI), which hopes to address drug shortage issues, after the FTC found the ARI will not be anticompetitive as sensitive information will be protected.

Fresenius cashes in on drug shortages

German healthcare conglomerate Fresenius has posted substantial growth across all regions and product areas during the first half of 2012 for its US business Fresenius Kabi. The growth has been largely attributed to rivals’ problems with supplying generics on the drug shortages list in the US.

Generics market set to increase in Japan

Japan has not been an easy place for drugmakers to do business. However, with government initiatives being introduced to increase generics use and taking into account the fact that Japan is currently the world’s second largest pharmaceutical market, it is perhaps not surprising that a new partnership is optimistic about the opportunities.

Sun Pharma finally gains full control of Taro

Sun Pharmaceutical Industries (Sun Pharma) and Taro Pharmaceutical Industries (Taro) announced on 13 August 2012 that they have entered into a merger agreement together. India-based Sun Pharma has agreed to pay out an additional US$600 million in order to finally gain full control of Israel-based Taro.

Generics News Research General


Biosimilars News Research General